Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-granulocyte colony stimulating factor fusion protein - Beijing BioFortune/Tianjin SinoBiotech

Drug Profile

Albumin-granulocyte colony stimulating factor fusion protein - Beijing BioFortune/Tianjin SinoBiotech

Alternative Names: Albumin-GCSF-fusion-protein-Tianjin-SinoBiotech/Beijing-BioFortune; HSA-G-CSF-fusion-protein-Tianjin; HSA-GCSF; Human Serum Albumin GCSF; Human-serum-albumin/granulocyte-colony-stimulating-factor-fusion-protein-Tianjin; Recombinant-albumin-granulocyte-colony-stimulating-factor-fusion-protein-Tianjin; rHSA/GCSF fusion protein - Tianjin SinoBiotech

Latest Information Update: 26 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Bio-Fortune; Tianjin SinoBiotech
  • Class Albumins; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 24 Apr 2019 Tianjin SinoBiotech completes a phase II trial for Neutropenia (Prevention, Chemotherapy-induced) in China (SC) (NCT03251768)
  • 06 Sep 2017 Albumin-granulocyte colony stimulating factor fusion protein is still in phase II trials for Neutropenia in China
  • 14 Aug 2017 Tianjin SinoBiotech initiates enrolment in a phase II trial for Neutropenia (Prevention, Chemotherapy-induced) in China (NCT03251768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top